New anticoagulants in children.
Thromboembolic complications are increasing in children and the use of anticoagulation has seen a dramatic increase despite the lack of randomized clinical trials. The most widely used agents in children are heparin, low-molecular-weight heparins (LMWH), and warfarin. These agents, however, have significant limitations that are exaggerated in children. Novel anticoagulants such as direct thrombin inhibitors and the selective factor Xa inhibitor, fondaparinux, have been approved for use in adults and have properties that suggest they may be safer and more efficacious than the standard agents; however, until recently, publications using these agents in children were limited to case reports. Recently, clinical trials for two direct thrombin inhibitors, bivalirudin and argatroban, have been completed and a clinical trial of fondaparinux is under way. This review will compare the standard agents with the novel agents and briefly review the results of the clinical trials.
Young
Guy
G
Children's Hospital Los Angeles, Los Angeles, CA 90027, USA. gyoung@chla.usc.edu
D000328:Adult; D000367:Age Factors; D000925:Anticoagulants / Q000266:history / Q000627:therapeutic use*; D002648:Child; D002986:Clinical Trials as Topic; D000077425:Fondaparinux; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use; D049673:History, 20th Century; D006801:Humans; D011134:Polysaccharides / Q000627:therapeutic use; D012449:Safety; D013923:Thromboembolism / Q000188:drug therapy* / Q000266:history; D014859:Warfarin / Q000627:therapeutic use
D000925:Anticoagulants; D006495:Heparin, Low-Molecular-Weight; D011134:Polysaccharides; D014859:Warfarin; D000077425:Fondaparinux